1328-P: Racial Differences in Comorbidities in Youth with T2D in the Pediatric Diabetes Consortium (PDC)

• DOI: 10.2337/db19-1328-p
• Publication Date: 2019-06-05T00:53:25Z
• Authors: FIDA BACHA; PEIYAO CHENG; ROBIN L. GAL; LINDSEY C. BEAULIEU; CRAIG KOLLMAN; ANNE ADOLPH; ISHITA JINDAL; ASHLEY H. SHOEMAKER; RISA M. WOLF; GEORGEANNA J. KLI...; WILLIAM V. TAMBOR...
• Keywords: Dyslipidemia; Medical record

Background: Racial differences in diabetes control and cardiovascular disease risk factors have been reported youth with diabetes, minority having worse glycemic comorbidities compared non-Hispanic white (NHW) peers. Methods: We examined racial (<21 years at enrollment) T2D (N=1217, 63% females) enrolled the PDC Registry from February 2012 to June 2018. Demographic clinical data collected medical records participant self-report were using logistic linear regression models adjusted for relevant confounders. Results: The mean age presentation was 13.4 ± 2.4 years, BMI Z-score 2.30 0.45. African-American (AA) Hispanic (H) had higher HbA1c lower C-peptide diagnosis NHW, AA 3 times as likely present DKA NHW. Microalbuminuria 11%, hypertension 34% dyslipidemia 42% no significant these among groups. Nonalcoholic fatty liver (NAFLD) diagnosed 9% 11% of H respectively vs. 2% (Table). Conclusion: Minority presented metabolic rates youth. Comorbidities exist a large percentage independent ethnicity, except NAFLD being less prevalent AA. Disclosure F. Bacha: Research Support; Self; National Institute Diabetes Digestive Kidney Diseases, Pediatric Consortium. Other Relationship; AstraZeneca, Jaeb Center Health Research. P. Cheng: None. R.L. Gal: L.C. Beaulieu: C. Kollman: A. Adolph: I. Jindal: A.H. Shoemaker: Advisory Panel; Rhythm Pharmaceuticals, Inc. GLWL Inc., Novo Nordisk Soleno Therapeutics. R.M. Wolf: G.J. Klingensmith: Consultant; Boehringer Ingelheim Takeda Pharmaceutical Company Limited. Foundation. Stock/Shareholder; Spouse/Partner; Dexcom, W.V. Tamborlane: International GmbH, Eli Lilly Company, Medtronic MiniMed, Sanofi, Funding Ingelheim; Nordisk; Limited